Addressing systemic barriers and implementing policies can reduce disparities in healthcare access and promote equity in treatment. Increasing awareness and education among healthcare providers ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current hormone therapies for prostate cancer and benign prostatic hyperplasia | ...

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...